Insight into the structural determinants for selective inhibition of matrix metalloproteinases.

The matrix metalloproteinase (MMP) family has been a pharmaceutical target for over 20 years. Despite massive research and development efforts, only one MMP inhibitor (Periostat) has been approved by the FDA for the treatment of periodontal disease. Possible reasons for the low success rate of MMP inhibitors in the clinic include unwanted side effects caused by their lack of selectivity, poor oral bioavailability and decreased potency in vivo. We review how three-dimensional structures (3D) of MMP inhibitor complexes as well as the inhibition profile of compounds screened on MMP can be used to guide the optimization of selectivity of MMP inhibitors. Analysis of MMP 3D structures provides a ranking of their pockets on the basis of opportunities for selective interactions. One can use inhibition data to build pharmacophore or quantitative structure-activity models (QSAR) for virtual screening of libraries of novel MMP inhibitors. Combining protein- and ligand-based approaches, we conclude that targeting a single pocket is not always sufficient to achieve the desired selectivity profile. Finally, we also outline novel series of selective MMP inhibitors that exploit differences in the intrinsic flexibility of the catalytic domain to form selective interactions with a given MMP.

[1]  D. Hadjipavlou-Litina,et al.  Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. , 2005, Current medicinal chemistry.

[2]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[3]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[4]  Paul Geladi,et al.  Principal Component Analysis , 1987, Comprehensive Chemometrics.

[5]  R. Reich,et al.  Recent non-hydroxamate matrix metalloproteinase inhibitors , 2005 .

[6]  Soumyendu Raha,et al.  Similarity of Binding Sites of Human Matrix Metalloproteinases*[boxs] , 2004, Journal of Biological Chemistry.

[7]  Seth M. Cohen,et al.  New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.

[8]  R. Powers,et al.  The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. , 2004, Current topics in medicinal chemistry.

[9]  Hans Matter,et al.  Recent advances in the design of matrix metalloprotease inhibitors. , 2004, Current opinion in drug discovery & development.

[10]  Thy-Hou Lin,et al.  A Ligand-Based Molecular Modeling Study on Some Matrix Metalloproteinase-1 Inhibitors Using Several 3D QSAR Techniques , 2004, J. Chem. Inf. Model..

[11]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[12]  M. Milla,et al.  Pronounced Diversity in Electronic and Chemical Properties between the Catalytic Zinc Sites of Tumor Necrosis Factor-α-converting Enzyme and Matrix Metalloproteinases despite Their High Structural Similarity* , 2004, Journal of Biological Chemistry.

[13]  Seth M Cohen,et al.  The Design of Inhibitors for Medicinally Relevant Metalloproteins , 2007, ChemMedChem.

[14]  Seth M Cohen,et al.  A new role for old ligands: discerning chelators for zinc metalloproteinases. , 2006, Journal of the American Chemical Society.

[15]  Sophie Perrier,et al.  Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. , 2004, Journal of molecular biology.

[16]  Wenfang Xu,et al.  Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. , 2006, Bioorganic & medicinal chemistry.

[17]  Paolo Tortorella,et al.  N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. , 2006, Bioorganic & medicinal chemistry letters.

[18]  Gabriele Cruciani,et al.  Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. , 2002, Journal of medicinal chemistry.

[19]  Gerhard Klebe,et al.  Identification and Mapping of Small-Molecule Binding Sites in Proteins: Computational Tools for Structure-Based Drug Design. , 2002 .

[20]  B. Fingleton,et al.  Matrix metalloproteinases as valid clinical targets. , 2007, Current pharmaceutical design.

[21]  Vito Calderone,et al.  Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors. , 2006, Bioorganic & medicinal chemistry.

[22]  S. Meroueh,et al.  Quest for selectivity in inhibition of matrix metalloproteinases. , 2004, Current topics in medicinal chemistry.

[23]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[24]  J Andrew McCammon,et al.  Potent, selective pyrone-based inhibitors of stromelysin-1. , 2005, Journal of the American Chemical Society.

[25]  Li Zhang,et al.  Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[26]  Armando Rossello,et al.  Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. , 2006, Bioorganic & medicinal chemistry.

[27]  K Ulrich Wendt,et al.  Structural basis for the highly selective inhibition of MMP-13. , 2005, Chemistry and Biology.

[28]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[29]  Hans Matter,et al.  Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. , 2006, Journal of medicinal chemistry.

[30]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[31]  B. G. Rao,et al.  Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.

[32]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.